ORR and PFSR 24 rates by dose in patients with melanoma, NSCLC, and RCC treated with nivolumab monotherapy
| MEL (N = 107) | NSCLC (N = 129) | RCC (N = 34) | ||||
|---|---|---|---|---|---|---|
| Dose (mg/kg) | ORR % (n/N) | PFSR 24, % | ORR % (n/N) | PFSR 24, % | ORR % (n/N) | PFSR 24, % |
| 0.1 | 35 (6/17) | 41 | — | — | — | — |
| 0.3 | 28 (5/18) | 35 | — | — | — | — |
| 1 | 31 (11/35) | 51 | 3 (1/33) | 26 | 28 (5/18) | 50 |
| 3 | 41 (7/17) | 55 | 24 (9/37) | 40 | — | — |
| 10 | 20 (4/20) | 35 | 20 (12/59) | 33 | 31 (5/16) | 67 |
— = not tested, MEL melanoma, NSCLC non-small cell lung cancer, ORR objective response rate, PFSR 24 progression-free survival rate at 24 weeks, RCC renal cell carcinoma